Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hemodynamic Phenotype-Based, Capillary Refill Time-Targeted Resuscitation In Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial (A2)

NCT05057611 is registered in ClinicalTrials.gov with Pontificia Universidad Catolica de Chile as lead sponsor.

NCT NCT05057611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05057611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hemodynamic Phenotype-Based, Capillary Refill Time-Targeted Resuscitation In Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial (A2)
Lead sponsor
Pontificia Universidad Catolica de Chile
Phase
Not applicable
Overall status
Unknown status
Start date
March 18, 2022
Completion date
June 30, 2025
Enrollment
1,500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

septic shock